144 related articles for article (PubMed ID: 1534366)
1. Valproate use associated with persistent hyperammonemia and mitochondrial injury in a child with Down's syndrome.
Kane RE; Kotagel S; Bacon BR; Vogler CA
J Pediatr Gastroenterol Nutr; 1992 Feb; 14(2):223-7. PubMed ID: 1534366
[TBL] [Abstract][Full Text] [Related]
2. Valproic acid and secondary hyperammonemia.
Rawat S; Borkowski WJ; Swick HM
Neurology; 1981 Sep; 31(9):1173-4. PubMed ID: 6791053
[TBL] [Abstract][Full Text] [Related]
3. Heterozygote ornithine transcarbamylase deficiency presenting as symptomatic hyperammonemia during initiation of valproate therapy.
Honeycutt D; Callahan K; Rutledge L; Evans B
Neurology; 1992 Mar; 42(3 Pt 1):666-8. PubMed ID: 1549234
[TBL] [Abstract][Full Text] [Related]
4. Topiramate-valproate-induced hyperammonemic encephalopathy syndrome: case report.
Cheung E; Wong V; Fung CW
J Child Neurol; 2005 Feb; 20(2):157-60. PubMed ID: 15794187
[TBL] [Abstract][Full Text] [Related]
5. Hyperammonemia and coma without hepatic dysfunction induced by valproate therapy.
Barrueto F; Hack JB
Acad Emerg Med; 2001 Oct; 8(10):999-1001. PubMed ID: 11581089
[TBL] [Abstract][Full Text] [Related]
6. [The problems of valproate therapy in severely handicapped children--valproate induced hyperammonemia and hypocarnitinemia].
Matsui K; Iwamoto H; Ohtsuki N; Kobayashi T; Miyake S; Yamada M
No To Hattatsu; 1991 Jan; 23(1):32-8. PubMed ID: 1825272
[TBL] [Abstract][Full Text] [Related]
7. Sodium valproate induced tremor in a patient with epilepsy and Down's syndrome.
Siniscalchi A; Gallelli L; Loizzo S; Tiziana A; Russo E; De Sarro G
Curr Drug Saf; 2013 Feb; 8(1):69-71. PubMed ID: 23656451
[TBL] [Abstract][Full Text] [Related]
8. Valproic acid-induced hyperammonemia in mentally retarded adults.
Williams CA; Tiefenbach S; McReynolds JW
Neurology; 1984 Apr; 34(4):550-3. PubMed ID: 6422325
[TBL] [Abstract][Full Text] [Related]
9. Haematological disturbances during long-term valproate therapy.
Brichard B; Vermylen C; Scheiff JM; Ninane J; Cornu G
Eur J Pediatr; 1994 May; 153(5):378-80. PubMed ID: 8033931
[TBL] [Abstract][Full Text] [Related]
10. Temporary pure red-cell aplasia during valproate monotherapy: clinical observations and spectral electroencephalographic aspects.
Farkas V; Szabó M; Rényi I; Kohlhéb O; Benninger C
J Child Neurol; 2000 Jul; 15(7):485-7. PubMed ID: 10921523
[TBL] [Abstract][Full Text] [Related]
11. Valproate-induced hyperammonemia - uncovering an underlying inherited metabolic disorder: a case report.
Mehta S; Tayabali S; Lachmann R
J Med Case Rep; 2018 May; 12(1):134. PubMed ID: 29769109
[TBL] [Abstract][Full Text] [Related]
12. Two cases of valproate-induced hyperammonemic encephalopathy without hepatic failure.
Panda S; Radhakrishnan K
J Assoc Physicians India; 2004 Sep; 52():746-8. PubMed ID: 15839456
[TBL] [Abstract][Full Text] [Related]
13. [Hyperammonemia in valproate therapy in children and adolescents].
Laub MC
Nervenarzt; 1986 May; 57(5):314-8. PubMed ID: 3088461
[TBL] [Abstract][Full Text] [Related]
14. Hematologic toxicity of sodium valproate.
Acharya S; Bussel JB
J Pediatr Hematol Oncol; 2000; 22(1):62-5. PubMed ID: 10695824
[TBL] [Abstract][Full Text] [Related]
15. Fatal hyperammonemia in a patient with systemic lupus erythematosus.
Ichikawa H; Amano T; Kawabata K; Kushiro M; Wada J; Nagake Y; Makino H
Intern Med; 1998 Aug; 37(8):700-3. PubMed ID: 9745859
[TBL] [Abstract][Full Text] [Related]
16. Salicylate potentiates valproate-induced hyperammonemia in the rat.
Uetrecht JP
Pharmacology; 1987; 34(5):279-85. PubMed ID: 3112809
[TBL] [Abstract][Full Text] [Related]
17. Valproate hepatotoxicity syndrome: hypotheses of pathogenesis.
Stephens JR; Levy RH
Pharm Weekbl Sci; 1992 Jun; 14(3A):118-21. PubMed ID: 1502010
[TBL] [Abstract][Full Text] [Related]
18. Valproate-Associated Hyperammonemic Encephalopathy: Clinical Correlates and Management Strategies in a Tertiary Care Center.
Vaidyanathan S; Chatorikar S; Praharaj SK; Munoli RN; Udupa ST
J Clin Psychopharmacol; 2023 Mar-Apr 01; 43(2):145-148. PubMed ID: 36795014
[TBL] [Abstract][Full Text] [Related]
19. [Hyperammonemia secondary to the use of valproic acid: case report].
Turcato Mde F; Fernandes RM; Wichert-Ana L; Funayama CA
Arq Neuropsiquiatr; 2005 Jun; 63(2A):364-6. PubMed ID: 16100994
[TBL] [Abstract][Full Text] [Related]
20. Valproate-associated hepatotoxicity and its biochemical mechanisms.
Eadie MJ; Hooper WD; Dickinson RG
Med Toxicol Adverse Drug Exp; 1988; 3(2):85-106. PubMed ID: 3131628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
